Pirtobrutinib for relapsed or refractory B-cell malignancies

Dr. Anthony Mato

The multinational phase 1-2 study BRUIN found that the reversible BTK inhibitor pirtobrutinib was safe and active in multiple B-cell malignancies, including in patients previously treated with covalent BTK inhibitors.